PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33731883-4 2021 Genetic polymorphisms of CYP2C9, the main enzyme involved in the metabolism of sulfonylureas, have been associated with the risk of severe hypoglycaemia, particularly in poor metabolizers carrying CYP2C9 *3/*3 genotype, and especially in the case of patients treated with glimepiride. glimepiride 272-283 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 25-31 33731883-4 2021 Genetic polymorphisms of CYP2C9, the main enzyme involved in the metabolism of sulfonylureas, have been associated with the risk of severe hypoglycaemia, particularly in poor metabolizers carrying CYP2C9 *3/*3 genotype, and especially in the case of patients treated with glimepiride. glimepiride 272-283 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 197-203 33731883-5 2021 The objectives of the present study were to evaluate the potential clinical and economic outcomes of using CYP2C9 genotype data to guide the management of SU regimen in patients initiating glimepiride therapy, and to identify factors affecting the cost-effectiveness of this treatment scheme. glimepiride 189-200 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 107-113 33731883-9 2021 In conclusion, the potential cost of CYP2C9 genotype-guided dosing for glimepiride therapy is relatively high, and associated with modest improvements with respect to the number of hypoglycaemia avoided, as compared with standard dosing. glimepiride 71-82 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 37-43 26569597-4 2016 CYP2C9-based interaction was investigated for both 2-oxo-clopidogrel and glimepiride using HLM and the recombinant CYP2C9 system. glimepiride 73-84 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 30030468-6 2018 The clearance of glimepiride and gliclazide in CYP2C9*2 and *3 was significantly reduced compared to the wild-type. glimepiride 17-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 47-53 30030468-7 2018 These findings collectively indicate that OATP1B1*5 and *15 and CYP2C9*2 and *3 have a significant effect on the transport and metabolism of glimepiride and gliclazide. glimepiride 141-152 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 64-70 30030468-0 2018 CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. glimepiride 80-91 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 30030468-2 2018 The aim of this study was to assess the effect of CYP2C9 and OATP1B1 genetic polymorphisms on the metabolism and transport of glimepiride and gliclazide. glimepiride 126-137 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 50-56 30030468-5 2018 Glimepiride in the presence of CYP2C9*1, *2 and *3 recombinase had Vmax values of 21.58 +- 7.78, 15.69 +- 5.59, and 9.17 +- 3.03 nmol/min/mg protein, while gliclazide had Vmax values of 15.73 +- 3.11, 10.53 +- 4.06, and 6.21 +- 2.94 nmol/min/mg protein, respectively. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 31-37 26569597-6 2016 For the metabolism of 2-oxo-clopidogrel (the second step of bioactivation), glimepiride demonstrated a relatively strong inhibition against CYP2C9 activity (IC50 12.7 mumol/l). glimepiride 76-87 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 140-146 26569597-7 2016 In addition, 2-oxo-clopidogrel displayed a moderate inhibitory effect toward the CYP2C9-mediated metabolism of glimepiride. glimepiride 111-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 81-87 24118918-0 2014 In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. glimepiride 103-114 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 26-32 24986093-0 2014 Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. glimepiride 38-49 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 86-92 24986093-2 2014 METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). glimepiride 90-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 126-151 24986093-2 2014 METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). glimepiride 90-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 161-167 24986093-2 2014 METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). glimepiride 90-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 171-177 24986093-2 2014 METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). glimepiride 90-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 171-177 24986093-2 2014 METHODS: In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16). glimepiride 90-101 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 171-177 24986093-3 2014 RESULTS: Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0.669 +- 0.055 microM, 0.424 +- 0.032 microM, 2.557 +- 0.058 microM, and 0.667 +- 0.039 microM, respectively. glimepiride 111-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 47-53 24986093-3 2014 RESULTS: Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0.669 +- 0.055 microM, 0.424 +- 0.032 microM, 2.557 +- 0.058 microM, and 0.667 +- 0.039 microM, respectively. glimepiride 111-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 58-64 24986093-3 2014 RESULTS: Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0.669 +- 0.055 microM, 0.424 +- 0.032 microM, 2.557 +- 0.058 microM, and 0.667 +- 0.039 microM, respectively. glimepiride 111-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 58-64 24986093-3 2014 RESULTS: Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0.669 +- 0.055 microM, 0.424 +- 0.032 microM, 2.557 +- 0.058 microM, and 0.667 +- 0.039 microM, respectively. glimepiride 111-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 58-64 24986093-4 2014 The inhibitory effect of glimepiride on losartan metabolism by CYP2C9*13 was marginal. glimepiride 25-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 63-69 24986093-5 2014 The apparent Ki value of glimepiride with CYP2C9*3 (0.0416 +- 0.0059 microM) was significantly lower than with CYP2C9*1 (0.1476 +- 0.0219 microM) and CYP2C9*16 (0.2671 +- 0.0456 microM). glimepiride 25-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 24986093-5 2014 The apparent Ki value of glimepiride with CYP2C9*3 (0.0416 +- 0.0059 microM) was significantly lower than with CYP2C9*1 (0.1476 +- 0.0219 microM) and CYP2C9*16 (0.2671 +- 0.0456 microM). glimepiride 25-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-117 24986093-5 2014 The apparent Ki value of glimepiride with CYP2C9*3 (0.0416 +- 0.0059 microM) was significantly lower than with CYP2C9*1 (0.1476 +- 0.0219 microM) and CYP2C9*16 (0.2671 +- 0.0456 microM). glimepiride 25-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 111-117 24986093-7 2014 The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 > CYP2C9*13 by 4 microM losartan. glimepiride 32-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 24986093-7 2014 The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 > CYP2C9*13 by 4 microM losartan. glimepiride 32-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 24986093-7 2014 The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 > CYP2C9*13 by 4 microM losartan. glimepiride 32-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 24986093-7 2014 The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 > CYP2C9*13 by 4 microM losartan. glimepiride 32-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 24986093-9 2014 CONCLUSIONS: Given these results, the potential inhibition of losartan metabolism by CYP2C9*3, CYP2C9*13, and CYP2C9*16 in vivo by glimepiride deserves further investigation. glimepiride 131-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 85-91 24986093-9 2014 CONCLUSIONS: Given these results, the potential inhibition of losartan metabolism by CYP2C9*3, CYP2C9*13, and CYP2C9*16 in vivo by glimepiride deserves further investigation. glimepiride 131-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 95-101 24986093-9 2014 CONCLUSIONS: Given these results, the potential inhibition of losartan metabolism by CYP2C9*3, CYP2C9*13, and CYP2C9*16 in vivo by glimepiride deserves further investigation. glimepiride 131-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 95-101 24118918-9 2014 This study provided the most comprehensive data on the enzymatic activities of all reported CYP2C9 variants in the Chinese population with regard to the commonly used antidiabetic drug, glimepiride. glimepiride 186-197 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 92-98 24118918-10 2014 Our results indicate that most of the tested rare alleles significantly decrease the catalytic activity of CYP2C9 variants towards glimepiride hydroxylation in vitro. glimepiride 131-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 107-113 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 24799741-7 2014 Patients with CYP2C9*1/*3 genotype showed greater mean glucose drop per milligram of drug values than patients with CYP2C9*1/*1 wild-type genotype for both glipizide and glimepiride while patients with CYP2C9*2/*3 genotype showed greater drop than patients with CYP2C9*1/*1 genotype only in the glipizide-treatment group. glimepiride 170-181 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 14-20 24799741-8 2014 The presence of CYP2C9*3 allele significantly affected plasma glucose drop per milligram of drug values in patients taking glipizide and glimepiride, while effects of CYP2C9*2 allele were insignificant. glimepiride 137-148 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 16-22 22360448-7 2012 Therefore, it should be taken into consideration that drugs metabolized by CYP2C9 in human could interact with rosuvastatin, as it has been already suggested for warfarin (rosuvastatin has increased its anticoagulant effect in human), and for telmisartan, sildenafil and glimepiride. glimepiride 271-282 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 75-81 21208246-0 2012 Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. glimepiride 94-105 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 21208246-11 2012 Our data on the one subject with this genotype suggest that CYP2C9*3/*3 momozygotes have lower clearance of glimepiride and are exposed to higher levels of the drug than wild-type homozygotes. glimepiride 108-119 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 60-66 20698928-0 2010 Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. glimepiride 146-157 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 20698928-2 2010 Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor. glimepiride 172-183 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 83-89 20698928-2 2010 Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor. glimepiride 172-183 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 230-236 20698928-2 2010 Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor. glimepiride 172-183 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 230-236 20698928-10 2010 CONCLUSIONS: Concomitant use of a CYP2C9 inhibitor results in exaggerated pharmacodynamic effects of sulphonylureas and increases the risk of hypoglycaemia in T2DM patients receiving glibenclamide, glimepiride or glipizide. glimepiride 198-209 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. glimepiride 192-203 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. glimepiride 192-203 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-85 19891554-3 2009 In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. glimepiride 192-203 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 79-85 23156991-5 2012 The results revealed that a combination of glimepiride with piperine led to the enhancement of the bioavailability of glimepiride by inhibiting the CYP2C9 enzyme, which suggested that piperine might be beneficial as an adjuvant to glimepiride in a proper dose, in diabetic patients. glimepiride 43-54 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 148-154 23156991-5 2012 The results revealed that a combination of glimepiride with piperine led to the enhancement of the bioavailability of glimepiride by inhibiting the CYP2C9 enzyme, which suggested that piperine might be beneficial as an adjuvant to glimepiride in a proper dose, in diabetic patients. glimepiride 118-129 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 148-154 23156991-5 2012 The results revealed that a combination of glimepiride with piperine led to the enhancement of the bioavailability of glimepiride by inhibiting the CYP2C9 enzyme, which suggested that piperine might be beneficial as an adjuvant to glimepiride in a proper dose, in diabetic patients. glimepiride 118-129 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 148-154 21476064-0 2011 Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. glimepiride 39-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 21476064-1 2011 PURPOSE: The purpose of this study was to develop a population pharmacokinetic (PPK) model of glimepiride and to investigate the influence of genetic polymorphisms in CYP2C9 on the PPK of glimepiride in healthy Korean subjects. glimepiride 188-199 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 167-173 21476064-6 2011 The CYP2C9 genotypes as covariate significantly (P < 0.001) influenced the apparent oral clearance (CL/F) of glimepiride. glimepiride 112-123 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 4-10 21476064-7 2011 The estimated CL/F of glimepiride was higher (1.60-fold) in CYP2C9*1/*1 subjects than in CYP2C9*1/*3 subjects. glimepiride 22-33 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 60-66 21476064-7 2011 The estimated CL/F of glimepiride was higher (1.60-fold) in CYP2C9*1/*1 subjects than in CYP2C9*1/*3 subjects. glimepiride 22-33 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 21476064-8 2011 CONCLUSIONS: This study indicates that genetic polymorphisms of CYP2C9 influence the substantial interindividual variability in the disposition of glimepiride, and these polymorphisms may affect the clinical response to glimepiride therapy. glimepiride 147-158 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 64-70 21476064-8 2011 CONCLUSIONS: This study indicates that genetic polymorphisms of CYP2C9 influence the substantial interindividual variability in the disposition of glimepiride, and these polymorphisms may affect the clinical response to glimepiride therapy. glimepiride 220-231 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 64-70 21121772-8 2010 However, a trend towards a lower stable glimepiride dose for carriers of the CYP2C9*3 allele was observed. glimepiride 40-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 77-83 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 43-49 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 19541829-8 2009 For glimepiride hydroxylation, the K(m) of CYP2C9.13 was increased 7-fold, and the V(max) values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. glimepiride 4-15 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 203-209 16372821-6 2005 Total oral clearance of all studied sulphonylureas (tolbutamide, glibenclamide [glyburide], glimepiride, glipizide) was only about 20% in persons with the CYP2C9*3/*3 genotype compared with carriers of the wild-type genotype CYP2C9*1/*1, and clearance in the heterozygous carriers was between 50% and 80% of that of the wild-type genotypes. glimepiride 92-103 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 155-161 16946524-2 2006 S-Warfarin 7-hydroxylation by recombinant CYP2C9.1 and CYP2C9.3 was inhibited by glimepiride competitively. glimepiride 81-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 16946524-2 2006 S-Warfarin 7-hydroxylation by recombinant CYP2C9.1 and CYP2C9.3 was inhibited by glimepiride competitively. glimepiride 81-92 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 55-61 16946524-3 2006 The apparent K(i) value of glimepiride was lower at CYP2C9.3 than at CYP2C9.1. glimepiride 27-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-58 16946524-3 2006 The apparent K(i) value of glimepiride was lower at CYP2C9.3 than at CYP2C9.1. glimepiride 27-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 69-75 16946524-4 2006 Glimepiride also inhibited 7-hydroxylation of S-warfarin in a competitive manner by microsomes from human liver which showed the genotypes of CYP2C9, as CYP2C9*1/*1 or CYP2C9*1/*3. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 142-148 16946524-4 2006 Glimepiride also inhibited 7-hydroxylation of S-warfarin in a competitive manner by microsomes from human liver which showed the genotypes of CYP2C9, as CYP2C9*1/*1 or CYP2C9*1/*3. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 153-159 16946524-4 2006 Glimepiride also inhibited 7-hydroxylation of S-warfarin in a competitive manner by microsomes from human liver which showed the genotypes of CYP2C9, as CYP2C9*1/*1 or CYP2C9*1/*3. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 153-159 16325295-0 2006 Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. glimepiride 79-90 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 16325295-1 2006 Glimepiride, a sulfonylurea hypoglycemic agent, is metabolized by cytochrome P450 2C9 (CYP2C9) which is known to have genetic polymorphisms. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 66-85 16325295-1 2006 Glimepiride, a sulfonylurea hypoglycemic agent, is metabolized by cytochrome P450 2C9 (CYP2C9) which is known to have genetic polymorphisms. glimepiride 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 87-93 16325295-4 2006 The long-term observations of 2 patients with a CYP2C9*1/*3 suggested that subjects with a CYP2C9*1/*3 respond well to glimepiride during the initial phase of treatment, but 1 patient have shown the weight gain over the long-term treatment. glimepiride 119-130 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 16325295-4 2006 The long-term observations of 2 patients with a CYP2C9*1/*3 suggested that subjects with a CYP2C9*1/*3 respond well to glimepiride during the initial phase of treatment, but 1 patient have shown the weight gain over the long-term treatment. glimepiride 119-130 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 16325295-5 2006 The pharmacokinetic study showed that the area under the concentration-time curve for glimepiride in the CYP2C9*1/*3 subjects was approximately 2.5-fold higher than that of the CYP2C9*1/*1 subjects. glimepiride 86-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 105-111 16325295-5 2006 The pharmacokinetic study showed that the area under the concentration-time curve for glimepiride in the CYP2C9*1/*3 subjects was approximately 2.5-fold higher than that of the CYP2C9*1/*1 subjects. glimepiride 86-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 177-183 16325295-6 2006 The intrinsic clearance of glimepiride by the CYP2C9*3 enzyme was lower than that by the CYP2C9*1 enzyme. glimepiride 27-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-52 16325295-6 2006 The intrinsic clearance of glimepiride by the CYP2C9*3 enzyme was lower than that by the CYP2C9*1 enzyme. glimepiride 27-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 16325295-7 2006 These results suggested that the lower hydroxylation activity of glimepiride in the subject with type 2 diabetes and CYP2C9*1/*3 led to a marked elevation in the plasma concentrations of glimepiride and a stronger pharmacological effect of glimepiride. glimepiride 65-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 117-123 16325295-7 2006 These results suggested that the lower hydroxylation activity of glimepiride in the subject with type 2 diabetes and CYP2C9*1/*3 led to a marked elevation in the plasma concentrations of glimepiride and a stronger pharmacological effect of glimepiride. glimepiride 187-198 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 117-123 16325295-7 2006 These results suggested that the lower hydroxylation activity of glimepiride in the subject with type 2 diabetes and CYP2C9*1/*3 led to a marked elevation in the plasma concentrations of glimepiride and a stronger pharmacological effect of glimepiride. glimepiride 187-198 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 117-123 11719730-1 2001 OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride, a new sulfonylurea antidiabetic drug and a substrate of cytochrome P4502C9 (CYP2C9). glimepiride 113-124 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 182-200 12235454-5 2002 However, in individuals heterozygous for the CYP2C9*3 allele, the median total area under the plasma concentration-time curve of glyburide (n = 2) was 280% (P < or = .05) and that of glimepiride (n = 3) was 267% (P < or = .01) of the respective values in subjects with the CYP2C9*1/*1 genotype (n = 5 and n = 12, respectively). glimepiride 186-197 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 12235454-7 2002 CONCLUSIONS: Genetic polymorphisms of CYP2C9 markedly affect the pharmacokinetics of both glyburide and glimepiride. glimepiride 104-115 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 38-44 12235454-8 2002 The influence of the CYP2C9*3 variant allele on glyburide and glimepiride pharmacokinetics may be clinically significant. glimepiride 62-73 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 21-27 11719730-1 2001 OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride, a new sulfonylurea antidiabetic drug and a substrate of cytochrome P4502C9 (CYP2C9). glimepiride 113-124 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 202-208 11309547-11 2001 This was probably caused by inhibition of the cytochrome P-450 2C9-mediated biotransformation of glimepiride by fluconazole. glimepiride 97-108 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-66 11136298-7 2000 CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance. glimepiride 66-77 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 11136298-7 2000 CONCLUSIONS: The effects of rifampicin on the pharmacokinetics of glimepiride suggest that rifampicin induced the CYP2C9-mediated metabolism of glimepiride and thereby slightly increased its systemic clearance. glimepiride 144-155 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 114-120 34727989-12 2021 CONCLUSIONS: Based on the clinical course and literature review, we believe that hypoglycemia in the present case was due to a drug interaction, caused by inhibition of CYP2C9 by bucolome and competitive inhibition of CYP2C9 by warfarin, which affected the pharmacokinetics of glimepiride. glimepiride 277-288 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 169-175 34727989-12 2021 CONCLUSIONS: Based on the clinical course and literature review, we believe that hypoglycemia in the present case was due to a drug interaction, caused by inhibition of CYP2C9 by bucolome and competitive inhibition of CYP2C9 by warfarin, which affected the pharmacokinetics of glimepiride. glimepiride 277-288 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 218-224